key: cord-0831377-khq2mzx2
authors: Flannery, Brendan; Meece, Jennifer K; Williams, John V; Martin, Emily T; Gaglani, Manjusha; Jackson, Michael L; Talbot, H Keipp
title: Systematic testing for influenza and COVID-19 among patients with respiratory illness
date: 2020-07-20
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1023
sha: f0d32e0fcaf5101221d7238821264503589016d4
doc_id: 831377
cord_uid: khq2mzx2

nan

M a n u s c r i p t 2 Dear Editor-A recent report by Rosenberg and colleagues highlights the importance of multiple sources of information for monitoring trends in the COVID-19 pandemic [1] . The authors use influenzalike illness (ILI) surveillance data and laboratory-confirmed influenza and COVID-19 cases to estimate population-based rates of illness during the beginnings of the pandemic in New York state. Because SARS-CoV-2 testing was rapidly increasing during this period in many areas of the U.S., numbers of COVID-19 cases were likely underestimated. This raises the question of whether COVID-19 contributed to ILI trends prior to widespread testing.

We recently examined the timing and extent of COVID-19 among patients with acute respiratory illness (ARI) enrolled in two U.S. influenza vaccine effectiveness networks [2, 3] . We retrospectively tested specimens collected between late January and mid-March 2020, a time period during which genomic analyses of SARS-CoV-2 isolates suggested silent community spread in several U.S. locations [4, 5, 6] .

In the influenza networks, outpatients aged ≥6 months and inpatients aged ≥18 years with ARI (defined as cough or respiratory symptoms with onset ≤10 days earlier) were enrolled during the influenza season at healthcare facilities associated with study sites in six states (Michigan, Pennsylvania, Tennessee, Texas, Washington and Wisconsin) [7] . During the influenza season, respiratory specimens including nasal, throat or nasopharyngeal swabs were prospectively tested for influenza by RT-PCR. We retrospectively tested a subset of stored specimens or extracted RNA at study sites for SARS-CoV-2 using RT-PCR designed to detect the SARS-CoV-2 nucleocapsid gene.

Although the number of confirmed influenza cases decreased after mid-February, influenza positivity among participants remained above 30% through early March, when enrollment was interrupted due to the COVID-19 pandemic (Figure) . Of 4961 specimens tested retrospectively, five (0.1%) specimens from patients at three study sites tested positive for SARS-CoV-2, all from patients enrolled within one

week of the first COVID-19 cases reported in surveillance counties (Table) . None of the patients had been previously identified as having COVID-19. Although few SARS-CoV-2 positive patients were A c c e p t e d M a n u s c r i p t 3 identified before facility-based enrollment was halted, timing of initial reports of COVID-19 cases in these surveillance areas coincided with detection of SARS-CoV-2 positive cases among outpatients and inpatients with respiratory symptoms.

Rapid increases in COVID-19 cases may have contributed to peaks in ILI activity observed in many states near the end of the influenza season, as suggested by computer modeling [8] , but changes in ambulatory care utilization may also have contributed. Given overlap between ARI/ILI and symptoms of mild/moderate COVID-19 [9] , systematic testing for SARS-CoV-2 and influenza will be needed during the upcoming influenza season to interpret trends in ILI surveillance and determine contributions of each viral illness to the burden of respiratory disease. Testing for both pathogens (and other respiratory viruses) may become routine for inpatients with respiratory illness but will depend upon availability and access to testing among patients with mild illness. Facility based surveillance for ILI and research studies will have to adapt. We agree with Rosenberg et al that alternatives to facility-based specimen collection, including home based nasal swabs or saliva collection, will be needed.

Monitoring COVID-19 through Trends in Influenzalike Illness and Laboratory-confirmed Influenza and COVID-19

Evidence for Limited Early Spread of COVID-19 Within the United States

SARS-CoV-2 Infections in Children -Multi-Center Surveillance

Early Detection of Covid-19 through a Citywide Pandemic Surveillance Platform

Introductions and early spread of SARS-CoV-2 in the New York City area

A Genomic Survey of SARS-CoV-2 Reveals Multiple Introductions into Northern California without a Predominant Lineage

Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness -United States

Using influenza surveillance networks to estimate statespecific case detection rates and forecast SARS-CoV-2 spread in the United States

SARS-CoV-2 detection in patients with influenza-like illness

A c c e p t e d M a n u s c r i p t 5 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t